Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE: 300255)
China
· Delayed Price · Currency is CNY 20.31
+0.49 (2.47%)
Dec 27, 2024, 3:04 PM CST
Hebei Changshan Biochemical Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 1,042 | 1,397 | 2,327 | 2,941 | 2,354 | 2,070 | Upgrade
|
| Other Revenue | 13.25 | 13.25 | 9.65 | 27.3 | 9.76 | 1.12 | Upgrade
|
| Revenue | 1,055 | 1,410 | 2,336 | 2,968 | 2,364 | 2,071 | Upgrade
|
| Revenue Growth (YoY) | -37.29% | -39.63% | -21.29% | 25.56% | 14.11% | 25.34% | Upgrade
|
| Cost of Revenue | 1,591 | 1,733 | 1,315 | 1,246 | 743.43 | 559.93 | Upgrade
|
| Gross Profit | -536.35 | -322.77 | 1,021 | 1,722 | 1,620 | 1,512 | Upgrade
|
| Selling, General & Admin | 302.67 | 630.71 | 739.69 | 1,220 | 1,098 | 1,046 | Upgrade
|
| Research & Development | 81.7 | 158.82 | 145.01 | 150.63 | 127.54 | 135.91 | Upgrade
|
| Other Operating Expenses | 5.7 | 17.24 | 22.02 | 26.77 | 23.71 | 25.61 | Upgrade
|
| Operating Expenses | 405.34 | 822.15 | 913.23 | 1,398 | 1,252 | 1,206 | Upgrade
|
| Operating Income | -941.69 | -1,145 | 107.99 | 324.06 | 368.78 | 305.15 | Upgrade
|
| Interest Expense | -87.73 | -96.41 | -93.04 | -62.29 | -55.81 | -46.59 | Upgrade
|
| Interest & Investment Income | 2.96 | 1.85 | 1.99 | 1.3 | 1.64 | 4.01 | Upgrade
|
| Currency Exchange Gain (Loss) | 4.76 | 4.76 | 6.69 | -4.4 | -6.47 | 0.57 | Upgrade
|
| Other Non Operating Income (Expenses) | -13.79 | -13.67 | -12.8 | -10.13 | -8.99 | -8.46 | Upgrade
|
| EBT Excluding Unusual Items | -1,035 | -1,248 | 10.84 | 248.54 | 299.15 | 254.68 | Upgrade
|
| Impairment of Goodwill | -1.78 | -1.78 | -1.78 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -5 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0 | -0 | -0.09 | -0.11 | -0.02 | -0.22 | Upgrade
|
| Asset Writedown | 122.75 | - | -0.27 | - | - | - | Upgrade
|
| Other Unusual Items | 64.26 | 18.49 | 9.41 | 11.98 | 2.42 | 11.7 | Upgrade
|
| Pretax Income | -850.27 | -1,232 | 18.12 | 260.41 | 301.56 | 261.16 | Upgrade
|
| Income Tax Expense | 30.75 | 16.46 | 7.96 | 29.15 | 50.42 | 38.73 | Upgrade
|
| Earnings From Continuing Operations | -881.02 | -1,248 | 10.16 | 231.26 | 251.14 | 222.43 | Upgrade
|
| Minority Interest in Earnings | 36.43 | 7.94 | 7.36 | 2.31 | 1.7 | 2.86 | Upgrade
|
| Net Income | -844.59 | -1,240 | 17.51 | 233.57 | 252.84 | 225.29 | Upgrade
|
| Net Income to Common | -844.59 | -1,240 | 17.51 | 233.57 | 252.84 | 225.29 | Upgrade
|
| Net Income Growth | - | - | -92.50% | -7.62% | 12.23% | 60.93% | Upgrade
|
| Shares Outstanding (Basic) | 772 | 919 | 876 | 934 | 936 | 939 | Upgrade
|
| Shares Outstanding (Diluted) | 772 | 919 | 876 | 934 | 936 | 939 | Upgrade
|
| Shares Change (YoY) | -8.98% | 4.91% | -6.27% | -0.23% | -0.24% | 0.58% | Upgrade
|
| EPS (Basic) | -1.09 | -1.35 | 0.02 | 0.25 | 0.27 | 0.24 | Upgrade
|
| EPS (Diluted) | -1.09 | -1.35 | 0.02 | 0.25 | 0.27 | 0.24 | Upgrade
|
| EPS Growth | - | - | -92.00% | -7.41% | 12.50% | 60.00% | Upgrade
|
| Free Cash Flow | 142.3 | -205.6 | -428.1 | -305.21 | -383.36 | -221.53 | Upgrade
|
| Free Cash Flow Per Share | 0.18 | -0.22 | -0.49 | -0.33 | -0.41 | -0.24 | Upgrade
|
| Dividend Per Share | - | - | 0.005 | 0.026 | - | 0.013 | Upgrade
|
| Dividend Growth | - | - | -80.77% | - | - | -53.57% | Upgrade
|
| Gross Margin | -50.85% | -22.88% | 43.71% | 58.01% | 68.55% | 72.97% | Upgrade
|
| Operating Margin | -89.27% | -81.18% | 4.62% | 10.92% | 15.60% | 14.73% | Upgrade
|
| Profit Margin | -80.07% | -87.93% | 0.75% | 7.87% | 10.70% | 10.88% | Upgrade
|
| Free Cash Flow Margin | 13.49% | -14.58% | -18.32% | -10.28% | -16.22% | -10.69% | Upgrade
|
| EBITDA | -854.46 | -1,071 | 164.93 | 379.86 | 424.06 | 357.44 | Upgrade
|
| EBITDA Margin | -81.00% | -75.91% | 7.06% | 12.80% | 17.94% | 17.26% | Upgrade
|
| D&A For EBITDA | 87.24 | 74.25 | 56.94 | 55.8 | 55.28 | 52.29 | Upgrade
|
| EBIT | -941.69 | -1,145 | 107.99 | 324.06 | 368.78 | 305.15 | Upgrade
|
| EBIT Margin | -89.27% | -81.18% | 4.62% | 10.92% | 15.60% | 14.73% | Upgrade
|
| Effective Tax Rate | - | - | 43.94% | 11.19% | 16.72% | 14.83% | Upgrade
|
| Revenue as Reported | 1,055 | 1,410 | 2,336 | 2,968 | 2,364 | 2,071 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.